New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests
- 21 April 2024
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (6) , 1084-1091
Abstract
Introduction: Mixing tests in activated partial thromboplastin time (APTT) are used for the differentiation between lupus anticoagulants (LA), coagulation inhibitors, and factor deficient samples with APTT prolongation. However, the indexes for the differentiation have not been established. The present study aimed to develop new mixing test indexes for the differentiation.Methods: Twenty‐six LA‐positive, 8 progressive coagulation factor VIII inhibitor, and 35 coagulation deficient samples were employed. APTT were measured for normal plasma, patient plasma, and mixing plasma prepared at a ratio of 1:1 proportion in both without incubation and 2 h‐incubation. New two parameters named as ALD50 and mixture plasma—patient plasma after Warming change rate Subtraction (WaS) calculated from the clotting times of normal, 1:1 mixing and patient samples with/without 2 h‐incubation were established. In the samples with WaS result of <10.2%, ALD50 of ≥87.8%, and < 87.8% were defined as LA and coagulation factor deficiency, respectively, and WaS of ≥10.2% defined progressive coagulation factor inhibitors.Results: Sensitivity and specificity to LA were 80.8% and 93.0% for ALD50, and sensitivity and specificity to progressive coagulation factor inhibitor were 100.0% and 100.0% for WaS, respectively. The agreement between sample classification and WaS‐ALD50 was 88.4% (61/69).Conclusions: ALD50 and WaS showed acceptable sensitivity and specificity to LA and progressive coagulation factor inhibitor, respectively. These indexes would be useful for the differentiation between LA, factor deficiency, and progressive coagulation factor inhibitor in the mixing tests.Keywords
This publication has 28 references indexed in Scilit:
- The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?Research and Practice in Thrombosis and Haemostasis, 2019
- Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulantResearch and Practice in Thrombosis and Haemostasis, 2019
- Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negativesPathology, 2019
- Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulantResearch and Practice in Thrombosis and Haemostasis, 2018
- New formulas for mixing test to discriminate between lupus anticoagulant and acquired hemophilia AThrombosis Research, 2016
- Mixing test specific cut-off is more sensitive at detecting lupus anticoagulants than index of circulating anticoagulantThrombosis Research, 2016
- Pathogenesis of antiphospholipid syndrome: understanding the antibodiesNature Reviews Rheumatology, 2011
- The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are appliedThrombosis Research, 2006
- Acquired hemophilia A: A concise reviewAmerican Journal of Hematology, 2005
- Conceptions and Misconceptions in Testing for Lupus AnticoagulantsJournal of Autoimmunity, 2000